替沙仑赛治疗筛查时年龄小于3岁的婴幼儿复发或难治性B细胞急性淋巴细胞白血病:一项国际多中心回顾性队列研究
该国际多中心回顾性队列研究在歐洲十国15家医院纳入38例筛查时小于3岁的复发或难治性B细胞前体急性淋巴细胞白血病患儿,35例接受替沙仑赛输注。中位随访14个月,12个月总生存率84%,无事件生存率69%,严格无事件生存率41%,安全性可接受。
要点
- 38例筛查患儿中35例(92%)接受替沙仑赛输注,29例(76%)为KMT2A重排。
- 12个月总生存率84%、无事件生存率69%、严格无事件生存率41%。
- 细胞因子释放综合征任何级别21/35(60%),≥3级5例(14%);神经毒性任何级别9例(26%),无重度。
核心结论
- 这些数据提示替沙仑赛对年幼儿童和婴儿B细胞前体急性淋巴细胞白血病具有抗肿瘤活性且安全性可接受。
研究设计与样本
- 国际多中心回顾性队列研究,在欧洲十国15家医院开展。
- 纳入2018年9月1日至2021年9月1日筛查时年龄小于3岁、按获批适应证筛查替沙仑赛治疗的复发或难治性B细胞前体急性淋巴细胞白血病患儿。
- 38例符合条件患儿被筛查,其中35例(92%)接受单次静脉输注替沙仑赛。
主要发现
- 38例中29例(76%)为KMT2A重排急性淋巴细胞白血病,25例(66%)既往异基因造血干细胞移植后复发。
- 既往非移植治疗中位2线(IQR 2-3);7例(18%)曾用伊诺妥单抗,14例(37%)曾用贝林妥欧单抗。
- 中位随访14个月(IQR 9-21),输注后12个月总生存率84%(64-93;5例死亡),无事件生存率69%(47-83;9例事件),严格无事件生存率41%(23-58;18例事件)。
- 12个月时持续B细胞发育不全概率70%(95%CI 46-84;7例事件)。
- 28例可测量疾病患者中24例(86%)达到可测量残留病阴性完全缓解(伴或不伴血液学恢复)。
关键数值与推荐
- 细胞因子释放综合征任何级别21/35(60%),3级或更差5例(14%)。
- 神经毒性任何级别9例(26%),无重度。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children aged younger than 3 years were excluded from the ELIANA phase 2 trial of tisagenlecleucel in children with acute lymphoblastic leukaemia. The feasibility, safety, and activity of tisagenlecleucel have not been defined in this group, the majority of whom have high-risk (KMT2A-rearranged) infant acute lymphoblastic leukaemia and historically poor outcomes despite intensification of chemotherapy, and for whom novel therapies are urgently needed. We aimed to provide real-world outcome analysis of the feasibility, activity, and safety of tisagenlecleucel in younger children and infants with acute lymphoblastic leukaemia. METHODS: We did an international, multicentre, retrospective cohort study at 15 hospitals across ten countries in Europe. Eligible patients were children aged younger than 3 years at screening between Sept 1, 2018, and Sept 1, 2021, who were screened for tisagenlecleucel therapy for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia according to licensed indications. Patients received a single intravenous infusion of tisagenlecleucel. We tracked chimeric antigen receptor T-cell therapy outcomes using a standardised data reporting form. Overall survival, event-free survival, stringent event-free survival, B-cell aplasia, and toxicity were assessed in all patients who received a tisagenlecleucel infusion. FINDINGS: 38 eligible patients were screened, of whom 35 (92%) received a tisagenlecleucel infusion. 29 (76%) of 38 patients had KMT2A-rearranged acute lymphoblastic leukaemia, and 25 (66%) had relapsed after previous allogeneic haematopoietic stem-cell transplantation (HSCT). Patients had previously received a median of 2 lines (IQR 2-3) of (non-HSCT) therapy. Seven (18%) of 38 patients had received inotuzumab and 14 (37%) had received blinatumomab. After a median of 14 months (IQR 9-21) of follow-up, overall survival at 12 months after tisagenlecleucel infusion was 84% (64-93; five patients had died), event-free survival was 69% (47-83; nine events), and stringent event-free survival was 41% (23-58; 18 events). The probability of ongoing B-cell aplasia was 70% (95% CI 46-84; seven events) at 12 months. Adverse events included cytokine release syndrome, which occurred at any grade in 21 (60%) of 35 patients and at grade 3 or worse in five (14%), and neurotoxicity at any grade in nine (26%), none of which were severe. Measurable residual disease-negative complete response with or without haematological recovery occurred in 24 (86%) of 28 patients who had measurable disease. INTERPRETATION: These data suggest that tisagenlecleucel has antitumour activity and has an acceptable safety profile for young children and infants with B-cell precursor acute lymphoblastic leukaemia. FUNDING: None.
引用
- Ghorashian S, Jacoby E, De Moerloose B, et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022. PMID: 36084658. doi:10.1016/S2352-3026(22)00225-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。